OncoVista Innovative Therapies
Developing anticancer therapies by utilizing tumor-associated biomarkers
About OncoVista Innovative Therapies
OncoVista Innovative Therapies, Inc. operates as a biopharmaceutical firm focused on creating targeted anticancer treatments by leveraging tumor-associated biomarkers. Founded in September 2004 and based in San Antonio, Texas, the company aimed to develop therapies that were both more effective and less toxic for cancer patients. The former Chairman, CEO, and President was Alexander L. Weis, who guided the company's strategy to advance its drug candidates and seek new licensing or acquisition opportunities.
The company's business model centered on the development and eventual commercialization of its proprietary drug candidates. Its primary market was oncology, serving patients with specific types of cancer that could be identified through biomarkers. OncoVista's strategy involved progressing its compounds through clinical trials to gain regulatory approval, which would then generate revenue through drug sales or licensing agreements. The company's pipeline included two main drug candidates. The first, Cordycepin (OVI-123), was developed for refractory TdT positive leukemias and had been granted orphan drug status by the U.S. Food & Drug Administration. The second candidate, L-Nucleoside Conjugates (OVI-117), was a Thymidylate Synthase (TS) inhibitor intended for solid tumors such as colon, breast, and prostate cancer. OVI-117 was designed to offer enhanced pharmacological properties, retaining efficacy while reducing toxicity.
A significant milestone included the sale of its majority holding in its German subsidiary, AdnaGen AG, which provided funds to advance its clinical programs. The company also received FDA approval in 2012 to begin Phase I clinical trials for OVI-117. However, OncoVista faced challenges, including a three-year litigation case that was settled in 2015. By 2016, the company was reported as dormant following the resignation of its board of directors, which resulted in the license rights for OVI-117 returning to the licensor, Lipitek International, Inc.
Source: Dealroom company dataNews
Open roles
OncoVista Innovative Therapies in the San Antonio ecosystem
The OncoVista Innovative Therapies office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- CPChicago Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about OncoVista Innovative Therapies on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See OncoVista Innovative Therapies on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

